Metrika gets US nod for HbA1c test:
This article was originally published in Clinica
Diagnostic firm Metrika has been given the green light to market in the US its point-of-care A1cNow INView multi-test system for monitoring levels of HbA1c, the current gold standard for diabetes control. Used in a doctor's office or at home, the pager-sized device provides laboratory-quality results in five minutes from a 10 microlitre finger prick sample. Doctors can then determine a patient's average blood sugar level over the previous 2-3 months, the Sunnyvale, California firm claims. Studies show that a 1% reduction in HbA1C can lower the risk of blindness, amputation, kidney and nerve disease by 40%. Metrika will introduce the system later this year.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.